Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Share-based Compensation (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Share-based Compensation data on record, last reported at $14.3 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 93.35% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $41.7 million, up 49.97%, while the annual FY2025 figure was $41.7 million, 49.97% up from the prior year.
  • Share-based Compensation reached $14.3 million in Q4 2025 per TARS's latest filing, up from $12.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $14.3 million in Q4 2025 and bottomed at $782000.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $5.9 million, with a median of $5.5 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 397.49% in 2021, then tumbled 51.33% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $2.2 million in 2021, then skyrocketed by 68.47% to $3.7 million in 2022, then surged by 49.33% to $5.5 million in 2023, then skyrocketed by 35.04% to $7.4 million in 2024, then soared by 93.35% to $14.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $14.3 million in Q4 2025, $12.2 million in Q3 2025, and $8.2 million in Q2 2025.